Ozempic maker Novo Nordisk invests $4bn to meet US ‘skinny jab’ demand

Pharma group plans plant in North Carolina to produce diabetes drug and weight-loss product WegovyBusiness live – latest updatesNovo Nordisk is to invest more than $4bn (£3.2bn) in US manufacturing as it battles to keep up with booming demand for its obesity and diabetes drugs Wegovy and Ozempic.Denmark’s biggest pharmaceuticals company said it would spend $4.1bn building a second filling and finishing facility in Clayton, North Carolina, one of the biggest manufacturing investments in its history. Its drugs are injected by users once a week, and come in pre-filled pens. Continue reading...

Ozempic maker Novo Nordisk invests $4bn to meet US ‘skinny jab’ demand

Pharma group plans plant in North Carolina to produce diabetes drug and weight-loss product Wegovy

Novo Nordisk is to invest more than $4bn (£3.2bn) in US manufacturing as it battles to keep up with booming demand for its obesity and diabetes drugs Wegovy and Ozempic.

Denmark’s biggest pharmaceuticals company said it would spend $4.1bn building a second filling and finishing facility in Clayton, North Carolina, one of the biggest manufacturing investments in its history. Its drugs are injected by users once a week, and come in pre-filled pens. Continue reading...